Monday, July 7, 2025 7/7/2025

9/14 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center

Award Number: U01DK116102
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/25/2017
PERIOD OF PERFORMANCE END DATE: 05/31/2028

Group Awards By:

View Award Description

9/14 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center - PROJECT SUMMARY/ABSTRACT Successful kidney transplant reverses many of the chronic abnormalities in chronic kidney disease (CKD) and has shown to improve not only quality of life but also patient survival compared to renal replacement therapy. It is vital to identify strategies that improve and prolong organ function. APOL1 risk alleles have been shown to explain in part the increased risk of African Americans compared to non-African American for end-stage kidney disease. However, the association of APOL1 alleles with kidney transplant outcomes such as deterioration of kidney function, acute rejection, and allograft loss as well as living donor health is unclear. APOL1 genotyping has the potential to reduce the discard of good-quality kidneys from AA donors and increase the number of transplants overall. We are responding to RFA-DK-22-506 – “APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Centers”, to continue as a clinical center that builds upon the accomplishments of our established multidisciplinary research group in the first phase. As a successful recruitment site with our aligned 19 transplant programs, the proposal builds upon an established infrastructure and our experience recruiting APOLLO participants. In Phase 1 of APOLLO, we have successfully consented 156 kidney transplant recipients and 12 living donors, with DNA on hand in 151 recipients (97%) and 12 donors (100%), across these centers. We propose to collect long-term follow-up data on all APOLLO participants. (Aim 1); to provide detailed clinical data and biospecimens on APOLLO participants from our CC providing unique data not available in national registries: kidney biopsy results, acute rejection types and treatment, recurrent disease, changes in immunosuppression, medical compliance, bacterial and viral infections, proteinuria, creatinine and donor specific HLA antibodies, among others (Aim 2); and to facilitate return of APOL1 genotype results to participants (Aim 3). We are committed to collaborative protocol development, sharing best practices, and team science to achieve the APOLLO’s objectives. The APOLLO network has established a high-quality resource (data and specimen repository of blood, urine, DNA, and RNA) for future basic, clinical and translational research in transplantation. The proposed research plan will have future diagnostic, prognostic and therapeutic implications. In addition, it could have policy implications as kidneys may need to be allocated in the future taking into account the donor APOL1 genotype. The proposed research plan, by improving our understanding of the impact of APOL1 gene in kidney transplantation, has the potential to dramatically impact public health and diminish kidney discards for transplantation.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2023	JOSLIN DIABETES CENTER, INC.	1 JOSLIN PL	BOSTON	MA	02215	SUFFOLK	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	002	5	4/1/2025	COMPETING CONTINUATION	$182,857
2025	2020	JOSLIN DIABETES CENTER, INC.	1 JOSLIN PL	BOSTON	MA	02215	SUFFOLK	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	4	4/1/2025	NON-COMPETING CONTINUATION	-$182,857
2025	2020	JOSLIN DIABETES CENTER, INC.	1 JOSLIN PL	BOSTON	MA	02215	SUFFOLK	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	4	1/8/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $170,000 )
2024	2024	JOSLIN DIABETES CENTER, INC.	1 JOSLIN PL	BOSTON	MA	02215	SUFFOLK	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	6	7/23/2024	NON-COMPETING CONTINUATION	$170,000
														Subtotal = $170,000

Issue Date FY: 2023 ( Subtotal = $324,000 )
2023	2023	JOSLIN DIABETES CENTER, INC.	1 JOSLIN PL	BOSTON	MA	02215	SUFFOLK	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	002	5	8/31/2023	COMPETING CONTINUATION	$324,000
2023	2020	JOSLIN DIABETES CENTER, INC.	1 JOSLIN PL	BOSTON	MA	02215	SUFFOLK	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	4	8/22/2023	NON-COMPETING CONTINUATION	$0
2023	2020	JOSLIN DIABETES CENTER, INC.	1 JOSLIN PL	BOSTON	MA	02215	SUFFOLK	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	4	6/20/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $324,000

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2020	JOSLIN DIABETES CENTER, INC.	1 JOSLIN PL	BOSTON	MA	02215	SUFFOLK	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	4	6/22/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $346,141 )
2020	2020	JOSLIN DIABETES CENTER, INC.	1 JOSLIN PL	BOSTON	MA	02215	SUFFOLK	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	4	7/8/2020	NON-COMPETING CONTINUATION	$346,141
2020	2020	JOSLIN DIABETES CENTER, INC.	1 JOSLIN PL	BOSTON	MA	02215	SUFFOLK	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	002	4	9/24/2020	NON-COMPETING CONTINUATION	$0
2020	2019	JOSLIN DIABETES CENTER, INC.	1 JOSLIN PL	BOSTON	MA	02215	SUFFOLK	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	3	4/9/2020	NON-COMPETING CONTINUATION	$0
														Subtotal = $346,141

Issue Date FY: 2019 ( Subtotal = $346,141 )
2019	2019	JOSLIN DIABETES CENTER, INC.	1 JOSLIN PL	BOSTON	MA	02215	SUFFOLK	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	3	7/12/2019	NON-COMPETING CONTINUATION	$346,141
2019	2018	JOSLIN DIABETES CENTER, INC.	1 JOSLIN PL	BOSTON	MA	02215	SUFFOLK	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	7/11/2019	NON-COMPETING CONTINUATION	$0
														Subtotal = $346,141

Issue Date FY: 2018 ( Subtotal = $354,675 )
2018	2018	JOSLIN DIABETES CENTER, INC.	1 JOSLIN PL	BOSTON	MA	02215	SUFFOLK	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	2	9/11/2018	SUPPLEMENT FOR EXPANSION	$84,825
2018	2018	JOSLIN DIABETES CENTER, INC.	1 JOSLIN PL	BOSTON	MA	02215	SUFFOLK	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	2	8/28/2018	NON-COMPETING CONTINUATION	$269,850
														Subtotal = $354,675

Issue Date FY: 2017 ( Subtotal = $286,818 )
2017	2017	JOSLIN DIABETES CENTER, INC.	1 JOSLIN PL	BOSTON	MA	02215	SUFFOLK	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	9/15/2017	NEW	$286,818
														Subtotal = $286,818

Grand Total All Awards = $1,827,775

Top

All Categories

About

Search

Reports

Data Submission

Award Information

9/14 APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) Clinical Center

Award Number: U01DK116102

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/25/2017

PERIOD OF PERFORMANCE END DATE: 05/31/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer